MMSI Merit Medical Systems Inc.

Merit Medical Launches the basixALPHA™ Inflation Device

Merit Medical Launches the basixALPHA™ Inflation Device

Ergonomic device provides fast inflation to streamline angioplasty procedures

SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA™ Inflation Device.

The basixALPHA is the latest addition to the Merit inflation device portfolio. Products include analog and digital devices with low- and high-pressure capacity for inflation, deflation, and measurement of pressures in angioplasty balloons. Merit’s commitment to excellence in inflation device technology has resulted in decades of industry leadership. More than 10 million procedures have been completed using Merit inflation devices worldwide.

The new ergonomic device is designed for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures. Angioplasty, a type of percutaneous coronary intervention (PCI), is used to open narrowed or blocked arteries. Opening blocked arteries facilitates blood flow to the heart, minimizing damage. More than 1.2 million coronary angioplasty procedures are performed each year within the US.1

“As a leader in inflation device technology, Merit understands that inflation devices serve as staples in the cath lab,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “To provide physicians with an improved device, we listened to their feedback and innovated the basixALPHA—a technology that delivers fast inflation when needed most. It fits well within our robust portfolio of inventive yet reliable inflation device technologies, helping to improve the physician experience and patient outcomes around the globe.”

1. Medical News Today. 2019. “What to Know About Angioplasty.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

|



EN
28/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer ...

Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ Securement Technology. The Prelude Wave is the latest innovation in Meri...

 PRESS RELEASE

Merit Medical Reports Second Quarter 2025 Results and Updates Full-Yea...

Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance Highlights† Reported revenue of $382.5 million, up 13.2%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectivelyGAAP operating margin of 12.3%, compared to 13.6% in prior year periodNon-GAAP operating margin* of 21.2%, compared to 20.1% in prior year periodGAAP EPS $0.54, down 11.6%Non-GAAP EPS* $1.01, up 9.8%Free cash flow* generation of $89.1 million over first six months of 2025, up 8.1% year-over-yearAcquired Biolife Delaware, L.L.C. (“Biolife”), a manufacturer ...

 PRESS RELEASE

Merit Medical Names Martha Aronson as New President and Chief Executiv...

Merit Medical Names Martha Aronson as New President and Chief Executive Officer Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today the appointment of Martha Aronson as Merit’s new President and Chief Executive Officer, effective October 3, 2025. Fred P. Lampropoulos will remain as Chairman of the Board, President and CEO ...

 PRESS RELEASE

Merit Medical Systems To Announce Second Quarter 2025 Results On July ...

Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 SOUTH JORDAN, Utah, July 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2025, after the close of the stock market on Wednesday, July 30, 2025. Merit plans to hold its investor conference call on the same day (Wednesday, July 30, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access ...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch